Experience

Pictor

• New Zealand
• Biotechnology Research
• 1 - 100 Employee

• Product Development Manager

  • Jul 2022 - Present



Pictor

• New Zealand
• Biotechnology Research
• 1 - 100 Employee

• Senior Assay Development Scientist

  • 2021 - 2022



University of Nottingham

• United Kingdom
• Research Services
• 700 & Above Employee

• Postdoctoral Research Fellow

  • 2016 - 2020

  My research focus was acute myeloid leukaemia with a mutated NPM1 gene. One of my key project aims was to develop a novel therapeutic to prevent the leukemogenic effect of mutant NPM1. To achieve this I developed a novel, targeted gene therapy designed to halt disease progression. The strategy was based on delivering therapeutic mRNA encapsulated in lipid nanoparticles. A successful application to the Nottinghamshire Leukaemia Appeal provided funding for proof of principal studies which demonstrated the effectiveness of the therapeutic in model systems.



Oncimmune

• United Kingdom
• Biotechnology
• 1 - 100 Employee

• Research Scientist

  • 2011 - 2012

  At Oncimmune, I was responsible for leading a team in the large-scale production of recombinant proteins commonly over expressed in individuals with various types of cancer. These proteins were used to detect auto antibodies produced in the early stages of cancer development providing a method for early diagnosis. At Oncimmune, I was responsible for leading a team in the large-scale production of recombinant proteins commonly over expressed in individuals with various types of cancer. These proteins were used to detect auto antibodies produced in the early stages of cancer development providing a method for early diagnosis.



The University of Auckland

• New Zealand
• Higher Education
• 700 & Above Employee

• Research Scientist

  • 2007 - 2011